


correvio



# Piper Jaffray Annual Healthcare Conference 2019


December 3, 2019



NASDAQ: CORV / TSX: CORV

- Certain statements in this presentation contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” under applicable Canadian securities legislation (collectively, “forward-looking statements”). Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that may not be based on historical fact. Forward-looking statements can often be identified by the use of terminology such as “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate.
- By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These forward-looking statements include, but are not limited to: statements relating to the Company’s plans to submit a regulatory filing for Trevynt in Europe in the second half of 2020; and statements relating to the approval of Brinavess by the FDA and the timing of any such approval. In particular, no statement herein should be understood to mean that: (i) that our resubmission will be deemed to be complete by the FDA; (ii) that the FDA will find our underlying clinical trial data to be acceptable; (iii) that the FDA will find our manufacturing sites acceptable and validate them; or (iv) that our NDA will ultimately be approved by the FDA. Furthermore, the timing of any action by the FDA and possible regulatory paths forward cannot be guaranteed, in that, for example: (i) the FDA plans to hold an Advisory Committee meeting; (ii) the FDA may miss its own required deadlines (including for example, the PDFUA date); and (iii) the FDA may require further information or additional clinical studies. Finally, no statement provided herein should be understood to provide an estimate of the current or future prevalence of atrial fibrillation or the market potential for Brinavess in the United States.
- By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. A detailed discussion of the risks and uncertainties facing Correvio Pharma Corp. (“Correvio”) are discussed in the annual reports and detailed from time to time in our other filings with the Securities and Exchange Commission (“SEC”) available at [www.sec.gov](http://www.sec.gov) and the Canadian securities regulatory authorities at [www.sedar.com](http://www.sedar.com). In particular, we direct your attention to Correvio’s Annual Report on Form 40-F for the year ended December 31, 2018 and to its quarterly report filed November 14, 2019 for the third quarter of 2019. All of the risks and uncertainties disclosed in these filings are hereby incorporated by reference in their entirety.
- While Correvio makes these forward-looking statements in good faith, given these risks, uncertainties and factors, you are cautioned not to place undue reliance on any forward-looking statements made in this presentation. All forward-looking statements made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements to reflect subsequent events or circumstances, except as required by law. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to their inherent uncertainty.

An established, **fully-integrated company**, with a large US cardioversion opportunity



Brinavess - NDA-stage acute care product, with a potential **~\$500M US dollar market opportunity**, ~20% penetration of total US atrial fibrillation patient population



# correvio

Generated **\$21.3M** in YTD revenue through September 30, 2019; **+8% vs same period in 2018**



**Sufficient resources** to fully execute the Brinavess US opportunity





- Following Type C meeting with FDA Correvio resubmitted Brinavess NDA in Q2 2019
- Resubmission accepted by FDA in July 2019
- FDA Advisory Committee scheduled for December 10, 2019
- PDUFA target action date of December 24, 2019
- Eligible to apply for formal patent extensions into 2031
- Exploring strategic transaction opportunities



## SPECTRUM

- Post authorization safety study (EU)
- 1,778 unique patients with 2,009 treatment episodes at 53 centers in 6 countries
- 70.2% efficacy with 12-minute median time to conversion
- Key safety observations:
  - Cumulative incidence of HOIs<sup>1</sup> were 0.8%, (95% CI: 0.5%-1.4%)
  - 28 SAEs reported for 26 patients
  - No deaths reported
  - No torsades des pointes



## 34 ISTs and Other Post-Approval Studies

- Brinavess has been the subject of 34 investigator-sponsored and post-marketing studies which have gathered extensive data in real-world clinical settings



**59K**

- Over 8 years of real-world experience from over 59,000 patients that have been exposed to Brinavess worldwide

1. HOIs defined as significant hypotension, ventricular arrhythmia, atrial flutter, or bradycardia





Presented  
SPECTRUM data  
at the upcoming  
European Society  
of Cardiology 2019  
Congress  
(Sept 2019; Paris)



Post hoc analysis of  
SPECTRUM patients  
specifically treated in the  
Emergency Dept selected  
for presentation at the  
upcoming American Heart  
Association 2019 Annual  
Meeting  
(Nov 16-18; Philadelphia)



Manuscript submitted  
to a prestigious U.S.  
medical journal for  
publication; to coincide  
with launch  
(first half of 2020)



Planning for a strong  
presence at the  
upcoming American  
College of Cardiology  
69<sup>th</sup> Annual Scientific  
Sessions & Expo  
(March 2020; Chicago)

## New SPECTRUM Data Presented at AHA 2019



- New *post hoc* analysis data
- 1,289 unique patients treated specifically in the ER
- 70.2% efficacy with 12-minute median time to conversion
- Median length of hospital stay was 7.5 hours; only 13% of patients were in hospital for >24 hours
- Key safety observations:
  - 12 AEs of special interest in 11 patients<sup>1</sup> (0.9%, [95% CI: 0.4%-1.5%])
  - No SAEs resulted in sequelae, no deaths, and no torsades des pointes

1. The most common of which was significant bradycardia (n=9, 0.6%)

# U.S. Market Opportunity – Key Research Findings




## Prevalence of Atrial Fibrillation

7.1 million unique patients annually and expected to grow to 9.8M annually by 2030



## Cardioversions Performed

According to actual claims data, there are currently >500K cardioversions performed annually in the US



## First New Treatment in 10 Years

If approved, Brinavess will address many of the real-world limitations of existing pharmacotherapy for cardioversion and DCCV



## \$1B Addressable Market Growing to \$1.9B by 2030













Independent research model projects Brinavess has the potential to generate >\$500M in annual gross sales, based on actual claims data

1. Market research commissioned by Correvio and conducted by a top-tier market research firm. Data collected from actual payors who process 1.3B claims from 1.5M healthcare providers covering 165M persons in the US annually.



# 4 EU Marketed Products and 2 Major Regulatory Decisions Upcoming

**\$21.3M** in YTD revenue through September 30, 2019; +8% vs same period in 2018

	Product Brand	Therapeutic Area	Partner / Innovator	Product Positioning
EU		Cardiovascular		<ul style="list-style-type: none"> <li>• 60+ countries</li> <li>• Limited/no promotion (genericized)</li> </ul>
		Cardiovascular		<ul style="list-style-type: none"> <li>• Nordics, DE, ES, limited UK (no FR, IT) + Distribution ER setting</li> <li>• More efficient and patient friendly pathway to NSR</li> </ul>
		Anti-infective		<ul style="list-style-type: none"> <li>• UK, FR, DE, Nordics plus small EU and Middle East</li> <li>• Hospital avoidance/discharge agent (LA Vanco)</li> <li>• Foundation of anti-infective sales force in those countries</li> </ul>
		Anti-infective		<ul style="list-style-type: none"> <li>• All of Europe, except the Nordics</li> <li>• Severely ill HAP patients at risk of complications</li> <li>• Gram+ and some Gram-</li> <li>• Potent against biofilm, rapid, favorable tolerability</li> </ul>
		Cardiovascular		<ul style="list-style-type: none"> <li>• All of Europe</li> <li>• Orphan/niche product</li> <li>• Switch from UTHR's Remodulin®</li> </ul>
US		Cardiovascular		<ul style="list-style-type: none"> <li>• Q2 2019 resubmission</li> <li>• PDUFA date December 24, 2019</li> </ul>

■ Projected Launch



**Trevyent**  
TREPROSTINIL SODIUM

**United  
Therapeutics**  
C O R P O R A T I O N

- ✓ FDA has accepted United Therapeutics' (NASDAQ: UTHR) Trevyent NDA
- ✓ Assigned a PDUFA date of April 27, 2020
- Correvio plans to submit a regulatory filing for TREVYENT in Europe in second half of 2020

*"[Trevyent] is going to be transformative for a very large segment of the pulmonary hypertension population, especially that segment that suffers from connective tissue disease."*

*"...truly a plug-and-play system."*


*"[Trevyent]...is going to allow us to significantly expand the reach of subcutaneous Remodulin... well beyond the number of patients that we have already been able to help and serve with that product."*

**~ Martine Rothblatt, Chairman & CEO, United Therapeutics, on Q3 2019 Earnings Call**



2019

2020



**\$21.3M**

In YTD 2019 revenue; on track to deliver 20% growth over 2018 full year revenues<sup>1</sup>

**\$13.8M**

Equity financing in August 2019 adds gross proceeds of \$13.8M

**\$19.7M**


As of September 30, 2019, cash, cash equivalents, and restricted cash of \$19.7M

**50.5M**

Shares outstanding  
(as of November 13, 2019)

<sup>1</sup> Full year 2018 revenues totaled \$28.7 million.

An established, **fully-integrated company**, with a large US cardioversion opportunity



Brinavess - NDA-stage acute care product, with a potential **~\$500M US dollar market opportunity**, ~20% penetration of total US atrial fibrillation patient population



# correvio

Generated **\$21.3M** in YTD revenue through September 30, 2019; **+8% vs same period in 2018**




**Sufficient resources** to fully execute the Brinavess US opportunity



# correvio

# Thank You!



## Investor Contacts

---

**Justin Renz**  
President and Chief Financial Officer  
Correvio Pharma Corp.  
800.330.9928  
[jrenz@correvio.com](mailto:jrenz@correvio.com)

**Argot Partners**  
**Michelle Carroll/Claudia Styslinger**  
212.600.1902  
[michelle@argotpartners.com](mailto:michelle@argotpartners.com)  
[claudia@argotpartners.com](mailto:claudia@argotpartners.com)

NASDAQ: CORV / TSX: CORV